Drugmaker Gilead Sciences Inc.

Last year, the U.S. National Institutes of Health allowed among its patented medications to be produced generically via the same group, but this the 1st cope with a private company. ‘We will work with Gilead and others to increase access to all people coping with HIV in developing countries,’ said Ellen ‘t Hoen, executive director of the Medicines Patent Pool. Other pharmaceutical companies, including F. Hoffman-La Roche, Sequoia Pharmaceuticals and ViiV Healthcare, a joint venture between GlaxoSmithKline Pfizer and PLC Inc., are in talks with the U.N.-led group. Other main drugmakers including Johnson and Johnson, Abbott Laboratories, and Merck & Co. Have so far declined to negotiate with the combined group.

Finally, the record compares maturing in mice to aging in humans. Several aging pathways were found to end up being the same, and these could be interesting because they’re relevant to human being aging and may also end up being scientifically studied in mice.

Agilent Technologies introduces mass spectrometry systems at ASMS 2014 Agilent Systems Inc. today presented mass spectrometry systems increasing efficiency criteria for biology and analytical chemistry analyses at the annual conference of the American Society of Mass Spectrometry. ‘Our ultimate objective is to create all mass spec evaluation routine, even while users look at significantly complex samples,’ stated Gustavo Salem, vice president and general manager, Agilent Biological Systems Division.Finally, the record compares maturing in mice to aging in humans. Several aging pathways were found to end up being the same, and these could be interesting because they’re relevant to human being aging and may also end up being scientifically studied in mice.

Agilent Technologies introduces mass spectrometry systems at ASMS 2014 Agilent Systems Inc. today presented mass spectrometry systems increasing efficiency criteria for biology and analytical chemistry analyses at the annual conference of the American Society of Mass Spectrometry. ‘Our ultimate objective is to create all mass spec evaluation routine, even while users look at significantly complex samples,’ stated Gustavo Salem, vice president and general manager, Agilent Biological Systems Division.